Aimmune begins patient enrolment in European Phase lll trial of AR101 for peanut allergy
US-based Aimmune Therapeutics has begun enrolling patients for the European Phase lll ARTEMIS (ARC010) clinical trial of its investigational biologic oral immunotherapy, AR101, to treat peanut allergy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Allergy & Immunology | Clinical Trials | Immunotherapy | Peanuts | Pharmaceuticals